The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Oncology Biomarker Market Research Report 2025
Synopsis
A biomarker is referred to as a traceable biomolecule, whose presence found in body fluids such as blood, serum, urine, and tumor fluid that indicates disease or an underlying condition such as cancer.
The global Oncology Biomarker market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Oncology Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Oncology Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Oncology Biomarker in Diagnostics is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Oncology Biomarker include Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Genomic Health, GlaxoSmithKline plc, Novartis AG, Merck & Co. and Pfizer, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Oncology Biomarker, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Biomarker.
Report Scope
The Oncology Biomarker market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oncology Biomarker market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Biomarker companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
Bristol-Myers Squibb
Eli Lilly and Company
F.Hoffmann-La Roche Ltd.
Genomic Health
GlaxoSmithKline plc
Novartis AG
Merck & Co.
Pfizer
Qiagen N.V.
Segment by Type
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Stomach Cancer
Others
Segment by Application
Diagnostics
Drug Discovery And Development
Prognostics
Risk Assessment
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncology Biomarker companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
A biomarker is referred to as a traceable biomolecule, whose presence found in body fluids such as blood, serum, urine, and tumor fluid that indicates disease or an underlying condition such as cancer.
The global Oncology Biomarker market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Oncology Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Oncology Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Oncology Biomarker in Diagnostics is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Oncology Biomarker include Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Genomic Health, GlaxoSmithKline plc, Novartis AG, Merck & Co. and Pfizer, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Oncology Biomarker, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Biomarker.
Report Scope
The Oncology Biomarker market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oncology Biomarker market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Biomarker companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
Bristol-Myers Squibb
Eli Lilly and Company
F.Hoffmann-La Roche Ltd.
Genomic Health
GlaxoSmithKline plc
Novartis AG
Merck & Co.
Pfizer
Qiagen N.V.
Segment by Type
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Stomach Cancer
Others
Segment by Application
Diagnostics
Drug Discovery And Development
Prognostics
Risk Assessment
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncology Biomarker companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncology Biomarker Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Lung Cancer
1.2.3 Breast Cancer
1.2.4 Colorectal Cancer
1.2.5 Prostate Cancer
1.2.6 Stomach Cancer
1.2.7 Others
1.3 Market by Application
1.3.1 Global Oncology Biomarker Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Diagnostics
1.3.3 Drug Discovery And Development
1.3.4 Prognostics
1.3.5 Risk Assessment
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oncology Biomarker Market Perspective (2019-2030)
2.2 Oncology Biomarker Growth Trends by Region
2.2.1 Global Oncology Biomarker Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Oncology Biomarker Historic Market Size by Region (2019-2024)
2.2.3 Oncology Biomarker Forecasted Market Size by Region (2025-2030)
2.3 Oncology Biomarker Market Dynamics
2.3.1 Oncology Biomarker Industry Trends
2.3.2 Oncology Biomarker Market Drivers
2.3.3 Oncology Biomarker Market Challenges
2.3.4 Oncology Biomarker Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncology Biomarker Players by Revenue
3.1.1 Global Top Oncology Biomarker Players by Revenue (2019-2024)
3.1.2 Global Oncology Biomarker Revenue Market Share by Players (2019-2024)
3.2 Global Oncology Biomarker Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oncology Biomarker Revenue
3.4 Global Oncology Biomarker Market Concentration Ratio
3.4.1 Global Oncology Biomarker Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncology Biomarker Revenue in 2023
3.5 Oncology Biomarker Key Players Head office and Area Served
3.6 Key Players Oncology Biomarker Product Solution and Service
3.7 Date of Enter into Oncology Biomarker Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncology Biomarker Breakdown Data by Type
4.1 Global Oncology Biomarker Historic Market Size by Type (2019-2024)
4.2 Global Oncology Biomarker Forecasted Market Size by Type (2025-2030)
5 Oncology Biomarker Breakdown Data by Application
5.1 Global Oncology Biomarker Historic Market Size by Application (2019-2024)
5.2 Global Oncology Biomarker Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Oncology Biomarker Market Size (2019-2030)
6.2 North America Oncology Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Oncology Biomarker Market Size by Country (2019-2024)
6.4 North America Oncology Biomarker Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oncology Biomarker Market Size (2019-2030)
7.2 Europe Oncology Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Oncology Biomarker Market Size by Country (2019-2024)
7.4 Europe Oncology Biomarker Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oncology Biomarker Market Size (2019-2030)
8.2 Asia-Pacific Oncology Biomarker Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Oncology Biomarker Market Size by Region (2019-2024)
8.4 Asia-Pacific Oncology Biomarker Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oncology Biomarker Market Size (2019-2030)
9.2 Latin America Oncology Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Oncology Biomarker Market Size by Country (2019-2024)
9.4 Latin America Oncology Biomarker Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncology Biomarker Market Size (2019-2030)
10.2 Middle East & Africa Oncology Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Oncology Biomarker Market Size by Country (2019-2024)
10.4 Middle East & Africa Oncology Biomarker Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Oncology Biomarker Introduction
11.1.4 Abbott Laboratories Revenue in Oncology Biomarker Business (2019-2024)
11.1.5 Abbott Laboratories Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Detail
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Oncology Biomarker Introduction
11.2.4 Bristol-Myers Squibb Revenue in Oncology Biomarker Business (2019-2024)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Eli Lilly and Company
11.3.1 Eli Lilly and Company Company Detail
11.3.2 Eli Lilly and Company Business Overview
11.3.3 Eli Lilly and Company Oncology Biomarker Introduction
11.3.4 Eli Lilly and Company Revenue in Oncology Biomarker Business (2019-2024)
11.3.5 Eli Lilly and Company Recent Development
11.4 F.Hoffmann-La Roche Ltd.
11.4.1 F.Hoffmann-La Roche Ltd. Company Detail
11.4.2 F.Hoffmann-La Roche Ltd. Business Overview
11.4.3 F.Hoffmann-La Roche Ltd. Oncology Biomarker Introduction
11.4.4 F.Hoffmann-La Roche Ltd. Revenue in Oncology Biomarker Business (2019-2024)
11.4.5 F.Hoffmann-La Roche Ltd. Recent Development
11.5 Genomic Health
11.5.1 Genomic Health Company Detail
11.5.2 Genomic Health Business Overview
11.5.3 Genomic Health Oncology Biomarker Introduction
11.5.4 Genomic Health Revenue in Oncology Biomarker Business (2019-2024)
11.5.5 Genomic Health Recent Development
11.6 GlaxoSmithKline plc
11.6.1 GlaxoSmithKline plc Company Detail
11.6.2 GlaxoSmithKline plc Business Overview
11.6.3 GlaxoSmithKline plc Oncology Biomarker Introduction
11.6.4 GlaxoSmithKline plc Revenue in Oncology Biomarker Business (2019-2024)
11.6.5 GlaxoSmithKline plc Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Detail
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Oncology Biomarker Introduction
11.7.4 Novartis AG Revenue in Oncology Biomarker Business (2019-2024)
11.7.5 Novartis AG Recent Development
11.8 Merck & Co.
11.8.1 Merck & Co. Company Detail
11.8.2 Merck & Co. Business Overview
11.8.3 Merck & Co. Oncology Biomarker Introduction
11.8.4 Merck & Co. Revenue in Oncology Biomarker Business (2019-2024)
11.8.5 Merck & Co. Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Detail
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Oncology Biomarker Introduction
11.9.4 Pfizer Revenue in Oncology Biomarker Business (2019-2024)
11.9.5 Pfizer Recent Development
11.10 Qiagen N.V.
11.10.1 Qiagen N.V. Company Detail
11.10.2 Qiagen N.V. Business Overview
11.10.3 Qiagen N.V. Oncology Biomarker Introduction
11.10.4 Qiagen N.V. Revenue in Oncology Biomarker Business (2019-2024)
11.10.5 Qiagen N.V. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
